Mammakarzinom

Schlüsselwörter

Mammakarzinom - Screening/Prävention, Therapie, Nachsorge

Key words

Breast cancer - Screening/prevention, therapy, aftercare

Literatur

• 1 Ries L. et al. National Cancer Institute .SEER cancer statistics review 1975 - 2001. URL http://seer.cancer.gov/csr/1975_2001/2004
• 2 Blanks R G, Moss S M, McGahan C E, Quinn M J, Babb P J. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990 - 8: comparison of observed with predicted mortality.  BMJ. 2000;  321 665-669
• 3 Verhoog L C, Brekelmans C TM, Seynaeve C. et al . Survival in hereditary breast cancer associated with germline mutations of BRCA 2.  JCO. 1999;  17 3396-3402
• 4 Cuzick J, Forbes J, Edwards R. et al . First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.  Lancet. 2002;  360 817-824
• 5 Fisher B, Costantino J P, Wickerham D L. et al . Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.  J Natl Cancer Inst. 1998;  90 1371-88
• 6 Cauley J A, Norton L, Lippman M E. et al . Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.  Breast Cancer Res Treat. 2001;  65 125-134
• 7 Eiermann W, Paepke S, Appfelstaedt J. et al . Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.  Ann Oncol. 2001;  12 1527-532
• 8 Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Jakesz R. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of th ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial.  Breast cancer Res Treat. 2005;  94 (suppl 1) , abstr 18
• 9 Coombes R C, Hall E, Gibson L J. et al . A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer.  N Engl J Med. 2004;  350 1081-1092
• 10 Goss P E, Ingle J N, Martino S. et al . A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer.  N Engl J Med. 2003;  349 1793-1802
• 11 Vicini F A, Horwitz E M, Lacerna M D. et al . The role of regional nodal irradiation in the management of patients with early-stage breast cancer treated with breast-conserving therapy.  Int J Radiat Oncol Biol Phys. 1997;  39 1069-1076
• 12 Gadd M, Harris J, Taghian A. et al . Prospective Study of axillary radiation without axillary dissection for breast cancer patients with a positive sentinel node.  Breast cancer Res Treat. 2005;  94 (suppl 1) , abstr 22
• 13 Martin M, Pienkowski T, Mackey J. et al . Adjuvant docetaxel for node-positive breast cancer.  Engl J Med. 2005;  352 2302-2313
• 14 Roche H, Fumoleau P, Spielmann M. et al . Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC 100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer.  Breast cancer Res Treat. 2004;  88 (suppl 1) , abstr 27
• 15 Henderson I C, Berry D A, Demetri G D. et al . Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.  J Clin Oncol. 2003;  21 976-983